Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Licenses TB Drug Sutezolid To Medicines Patent Pool

Deal Could Speed Up Development After Six-Year Hiatus

Executive Summary

Pfizer and the Medicines Patent Pool have signed a licensing agreement for the US firm’s investigational TB compound, sutezolid. The move should help to speed up the availability of the product, whose development appears to have been stalled since 2013.

You may also be interested in...

Patent Pool Strikes Deals with Cipla, Pfizer For New HIV, TB Drugs

The Medicines Patent Pool, a UN-backed public health organization, has announced deals with two major global pharma firms aimed at providing innovative, effective and affordable treatment for people - including children - living with HIV and TB. 

Medicines Patent Pool Strikes HIV Deal With Cipla

The Medicines Patent Pool, the UN-backed public health organization, has announced deals with Cipla and Pfizer covering HIV and TB drugs.

New Patent Pool Deal For TB Drug Abandoned By Pfizer Could Spark Development

A new licensing deal between the Medicines Patent Pool and a leading academic center for a Phase II tuberculosis drug candidate originally in development by Pfizer could signal a real opportunity for getting a commercially challenging product to market. Public health groups, while welcoming the move, have noted that the deal is no guarantee that the medicine will actually reach the patients who need it, though.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts